Allakos, Inc.
(NASDAQ : ALLK)

( )
ALLK PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
BMYBristol-Myers Squibb Co. 0.03%66.801.0%$728.32m
JNJJohnson & Johnson 0.01%148.250.7%$718.14m
PFEPfizer Inc. 0.10%40.640.9%$621.94m
MRKMerck & Co., Inc. 0.45%91.590.7%$587.37m
ABBVAbbVie, Inc. -0.19%89.102.3%$538.51m
LLYEli Lilly & Co. 0.01%141.431.1%$422.95m
APLSApellis Pharmaceuticals, Inc. -3.99%40.380.0%$108.01m
AZNAstraZeneca Plc 1.94%51.481.2%$100.38m
NVSNovartis AG 0.72%95.800.2%$99.54m
GSKGlaxoSmithKline Plc 2.11%48.150.2%$82.80m
SNYSanofi 0.00%51.190.2%$75.38m
NVONovo Nordisk A/S 0.15%61.380.1%$67.17m
RETAReata Pharmaceuticals, Inc. 1.80%216.273.5%$67.01m
KRTXKaruna Therapeutics, Inc. 0.00%95.740.0%$59.26m
TPTXTurning Point Therapeutics, Inc. 8.38%58.360.0%$41.00m

Company Profile

Allakos, Inc. engages in the development of therapeutic antibodies. Its primary product is AK002, a monoclonal antibody used for the treatment of various eosinophil and mast cell related diseases such as eosinophilic gastritis, urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis. The company was founded by Christopher Bebbington, Nenad Tomasevic, Bruce S. Bochner, and Robert Schleimer in 2012 and is headquartered in Redwood, CA.